Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema.

Trial Profile

Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Icatibant (Primary)
  • Indications Hereditary angioedema
  • Focus Therapeutic Use
  • Acronyms FAST-1
  • Sponsors Shire
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Apr 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top